State Street SPDR S&P Biotech ETF
123 hedge funds and large institutions have $1.6B invested in State Street SPDR S&P Biotech ETF in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 56 reducing their positions, and 29 closing their positions.
16.59% more ownership
Funds ownership: 387.44% → 404.03% (+17%)
1% less capital invested
Capital invested by funds: $1.62B → $1.6B (-$23.4M)
6% less funds holding
Funds holding: 131 → 123 (-8)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 56
78% less call options, than puts
Call options by funds: $10.7M | Put options by funds: $48.9M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$96.6M |
| 2 |
U
UBS
Zurich,
Switzerland
|
+$38.2M |
| 3 |
SCM
Sandler Capital Management
New York
|
+$17.9M |
| 4 |
Barclays
London,
United Kingdom
|
+$13.7M |
| 5 |
Morgan Stanley
New York
|
+$9.46M |
Top Sellers
XBI Hedge Fund Activity: Q2 2014 in Review
123 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2014, worth a combined $1.6B — down 1.4% from $1.62B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of XBI and 22 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 26 added.
The largest buyer was Goldman Sachs, adding an estimated $96.6M. The largest seller was Mirae Asset Global Investments, cutting an estimated $97.2M.
- 123 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2014, down from 131 in Q1 2014.
- Funds reported $1.6B of State Street SPDR S&P Biotech ETF stock for Q2 2014, down 1.4% quarter-over-quarter.
- 22 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2014 and 29 closed out, a net change of -7 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2014 was Goldman Sachs, an estimated $96.6M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2014 was Mirae Asset Global Investments, an estimated $97.2M sold.
Based on aggregated 13F filings for Q2 2014.